

GP 1055

TELEPHONE: 512/536-5201  
FACSIMILE: 512/536-5201

MARK B. WILSON  
PARTNER

INTERNET ADDRESS:  
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

RECEIVED

OCT 22 2001

TECH CENTER 1600/2900

October 15, 2001

FILE: AMBI:052US  
10022802

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:	
October 15, 2001 Date	 Mark B. Wilson

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/669,301 "NUCLEASE INHIBITOR COCKTAIL" - Kudlicki et al.

Sir:

Please find enclosed:


1. Response to Restriction Requirement dated September 14, 2001; and
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

It is believed that no fees under 37 C.F.R. §§ 1.16 to 1.21 are occasioned by the filing of this paper, however, should the Commissioner determine otherwise, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10022802/MBW.

Respectfully submitted,

Mark B. Wilson  
Reg. No. 37,259

MBW:plm  
Encl.



RECEIVED  
OCT 22 2001  
TECH CENTER 1600/2900

#7  
10/23/01  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

W. Antoni Kudlicki  
Matthew M. Winkler and  
Brittan L. Pasloske

Group Art Unit: 1655

Examiner: A. Chakrabarti

Serial No.: 09/669,301

Atty. Dkt. No.: AMBI:052US/MBW

Filed: September 25, 2000

For: NUCLEASE INHIBITOR COCKTAIL

CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:

October 15, 2001  
Date

*Mark B. Wilson*  
Mark B. Wilson

**RESPONSE TO RESTRICTION REQUIREMENT  
DATED SEPTEMBER 14, 2001**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Restriction Requirement dated September 14, 2001, for which the date for response is October 14, 2001. Since October 14, 2001, falls on a Sunday, the actual due date for response is October 15, 2001, pursuant to 37 C.F.R. §1.7(a).

It is believed that no fee is due relating to this response; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10022802/MBW.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-23 and 37-49, *i.e.*, the Group I claims, drawn to a method of inhibiting the nuclease enzyme.

The Examiner is invited to contact the undersigned attorney at (512) 536-3035 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.536.3035 (voice)  
512.536.4598 (fax)

Date: October 15, 2001